NCT07595224Recruiting
Postoperative Hypofractionated Whole Pelvic Radiotherapy in Cervical and Endometrial Cancer
PostOPerative HYPOfractionated Whole Pelvic Radiotherapy in Cervical (Cx) and Endometrial Cancer (PostOP HYPOCxE Trial) : A Phase II Non-inferiority Randomized Controlled Trial
Source: ClinicalTrials.gov · Last updated 19 May 2026
Brief summary (registry, in English)
This study aims to evaluate a shorter course of postoperative pelvic radiotherapy in patients with cervical and endometrial cancer. The standard radiotherapy schedule usually requires many treatment sessions over several weeks, which can be burdensome for patients and may affect their ability to complete treatment. This study will compare a shorter radiotherapy schedule (hypofractionated radiotherapy) with the standard schedule. Both treatments deliver a similar total radiation dose, but the shorter schedule reduces the number of hospital visits and overall treatment time. Participants will be randomly assigned to receive either the shorter or standard radiotherapy after surgery. The study will evaluate side effects, treatment effectiveness, and quality of life. The goal is to determine whether the shorter treatment is as safe and effective as the standard approach.
- Status (registry)
- Recruiting
- Study type
- Interventional
- Enrollment
- 120 (estimated)
- First submitted
- 16 Apr 2026
- Start date
- Mar 2026
- Primary completion date
- Dec 2026
- Lead sponsor
- Siriraj Hospital
- Diseases
- Endometrial cancer, Cervical cancer
- NCT number
- NCT07595224
What you commit to
- Study type: Interventional
- Planned participants: 120
- From Mar 2026 to the primary completion date, Dec 2026
- 1 site in 1 country
- Visits and tests: ask the trial team, the registry does not list them
Built from the registry fields of ClinicalTrials.gov. It describes the study, not your situation.
Who cannot take part
Copied verbatim from ClinicalTrials.gov and grouped by topic. Only the trial team decides who can take part.
Prior treatment
- Previous pelvic or abdominal radiotherapy
- Combination of preoperative chemotherapy or radiotherapy with surgery
Other illness
- Other primary malignancies except carcinoma in situ of the cervix and basal cell carcinoma of the skin
- Small cell neuroendocrine cancer, melanoma, uterine sarcoma, and other rare cancers in the cervix and uterus
- Metastatic disease beyond intervertebral disc L2/3 level
Other
- Contra-indications to EBRT
Who the study is looking for
- Pathologically proven carcinoma of the uterine cervix; and carcinoma and carcinosarcoma of uterine corpus
- Hysterectomy (total abdominal hysterectomy, vaginal hysterectomy, total laparoscopic hysterectomy or radical hysterectomy) for cancer of the cervix or endometrium within 49 days prior to registration. Hence inadvertent surgery will be allowed for inclusion.
- Indicated for adjuvant EBRT from multidisciplinary team discussion.
- Non-metastatic stage according to FIGO 2018 for Cervical cancer and FIGO 2023 for Endometrial cancer and TNM guidelines from appropriate diagnostic workup 4.1 History/physical examination within 45 days prior to registration 4.2 CT/MRI/PET-CT of abdomen/pelvis demonstrating the absence of distant metastasis, performed pre- or post-surgery within 90 days prior to registration 4.3 Chest x-ray or chest CT (or a PET/CT) performed within 90 days prior to registration
- Age ≥18 years old with informed consent
Age in the registry: 18 years to - · Sex: All · Does not accept healthy volunteers
Sites (1)
Sites in registry order. Pick your city on the disease page to sort them by distance.
| Site | City | Country | Site status |
|---|---|---|---|
| Siriraj Hospital Coordinator of this site? Confirm its status | Bangkok | Thailand | Recruiting |
This page is information, not medical advice. Discuss any trial with your doctor.